Reported 2 months ago
Morgan Stanley analysts anticipate significant gains in two biotech stocks, CervoMed (CRVO) and Viking Therapeutics (VKTX), driven by potential Federal Reserve interest rate cuts. Both companies have promising drug candidates in their pipelines, with CervoMed's promising results from clinical trials for neurodegenerative diseases potentially leading to a 230% price increase, while Viking Therapeutics aims to address obesity and metabolic disorders with an anticipated 98% upside. The analysts provide a 'Strong Buy' rating, highlighting encouraging clinical trial data and strategic upcoming catalysts.
Source: YAHOO